BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [PMID: 35611205 DOI: 10.12998/wjcc.v10.i11.3321]
URL: https://www.wjgnet.com/2307-8960/full/v10/i11/3321.htm
Number Citing Articles
1
Wenlong Zhu, Yanjie Zhang, Runze Jiang, Li Wang, Jin Ding. Hepatocellular carcinoma metastasis–immune microenvironment crosstalk: emerging mechanisms and immunotherapy. Cellular & Molecular Biology Letters 2026; 31(1) doi: 10.1186/s11658-026-00979-9
2
Reza Elahi, Yassine Alami Idrissi, Anwaar Saeed. CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation. Cancer Treatment Reviews 2025; 141 doi: 10.1016/j.ctrv.2025.103046
3
Min Yao, Ping Zhou, Yan-Yan Qin, Li Wang, Deng-Fu Yao. Mitochondrial carnitine palmitoyltransferase-II dysfunction: A possible novel mechanism for nonalcoholic fatty liver disease in hepatocarcinogenesis. World Journal of Gastroenterology 2023; 29(12): 1765-1778 doi: 10.3748/wjg.v29.i12.1765
4
Min Yao, Rong-Fei Fang, Qun Xie, Min Xu, Wen-Li Sai, Deng-Fu Yao. Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(6): 2350-2361 doi: 10.4251/wjgo.v16.i6.2350
5
Qing Li, Tianyi Wang, Ximin Wang, XinYu Ge, Tao Yang, Wei Wang. DDX56 promotes EMT and cancer stemness via MELK-FOXM1 axis in hepatocellular carcinoma. iScience 2024; 27(6) doi: 10.1016/j.isci.2024.109827